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Renal cell carcinomaAbstract Background: To determine suitability of progression-free survival (PFS) as a surro-
gate end-point for overall survival (OS), we evaluated the relationship between PFS and OS in
750 treatment-naı¨ve metastatic renal cell carcinoma (mRCC) patients who received sunitinib
or interferon-alpha (IFN-a) in a phase III study.
Methods: The relationship between PFS and post-progression survival (PPS; the difference
between PFS and OS) was studied, which correctly removes inherent dependencies between
PFS and OS, to properly estimate whether and to what extent PFS can serve as a surrogate
for OS. A Weibull parametric model to failure time data was ﬁt to determine whether longer
PFS was signiﬁcantly and meaningfully predictive of longer PPS. In a sensitivity analysis by
Kaplan–Meier non-parametric method, PPS curves for three approximately equal numbered
groups of patients categorised by PFS were compared by log-rank test.
Results: In the Weibull parametric model, longer PFS was signiﬁcantly predictive of longer
PPS (P < 0.001). The model also allowed prediction of estimated median PPS duration from
actual PFS times. In the Kaplan–Meier (non-parametric) analysis, incrementally longer PFS
S. Ne´grier et al. / European Journal of Cancer 50 (2014) 1766–1771 1767was also associated with longer PPS, and the PPS curves for the three PFS groups were
signiﬁcantly different (P < 0.0001).
Conclusions: A positive relationship was found between PFS and PPS duration in individual
mRCC patients randomised to ﬁrst-line treatment with sunitinib or IFN-a. These results indi-
cate that PFS can act as a surrogate end-point for OS in the ﬁrst-line mRCC setting and provide
clinical researchers with a potentially useful approach to estimate median PPS based on PFS.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Overall survival (OS) is the traditional gold standard
of clinical end-points in oncology trials. However, pow-
ering clinical trials to show treatment-group diﬀerences
in OS can be challenging given the length of post-pro-
gression survival (PPS), patient heterogeneity and vari-
ability in use of active treatments after disease
progression. These factors can dilute diﬀerences in OS,
requiring very large sample sizes and increasing the time
and cost associated with drug development [1], conse-
quently limiting or delaying treatment options for
patients. For example, Di Leo et al. [2] critically assessed
the ﬁndings of a number of phase III colorectal and
breast cancer trials and reported that sample sizes were
likely too small to detect realistic survival diﬀerences,
even in the presence of response rate and time to pro-
gression beneﬁts; they concluded that OS may not be a
realistic end-point for clinical trials of new drugs in
advanced solid tumours, especially for those tumours
with a number of post-progression treatment options.
Establishing one or more disease-progression end-
points as a valid surrogate for OS in pivotal clinical
studies could bring considerable beneﬁt to patients.
Among the various end-points proposed as surrogates
for OS, progression-free survival (PFS) has increasingly
taken the lead [3]. The suitability of PFS as an OS sur-
rogate has been investigated in various tumour types,
including cancers of the stomach, lung, breast and colo-
rectum [4–9]. However, equivalent studies in renal cell
carcinoma (RCC) are scarce, with only limited evidence
available from a retrospective meta-analysis and land-
mark analysis [10,11].
The introduction of targeted therapies has revolu-
tionised the treatment of metastatic RCC (mRCC),
and most of the clinical trials of agents that target the
vascular endothelial growth factor (VEGF) and mam-
malian target of rapamycin (mTOR) pathways have
used PFS as the primary end-point. Although, in the
past, regulatory agencies have viewed surrogate end-
points with caution, sunitinib, sorafenib, pazopanib,
everolimus and bevacizumab have all gained regulatory
approval on the basis of clinical trials that demonstrated
a PFS beneﬁt [12–17]. The majority of these trials did
not demonstrate an OS beneﬁt, and crossover and
post-study cancer treatment were cited as confounding
factors, since patients initially randomised to the controlarm were allowed to receive the active agent or similar
second- and third-line treatments, which may have
diluted any true OS beneﬁt [1].
The availability of subsequent lines of targeted thera-
pies may make it diﬃcult to prove OS beneﬁt in future
clinical trials of ﬁrst-line mRCC treatment. In a recently
published retrospective analysis of PFS as a predictor of
OS in patients with mRCC, Heng and colleagues con-
cluded that PFS may be the only end-point that is not
aﬀected by issues of crossover and contamination in tri-
als of contemporary targeted therapies [11]. They cau-
tioned, however, that prospective evaluation will be
required to conﬁrm these ﬁndings.
A variety of methodological approaches have been
used to assess surrogacy. Although many surrogate-
end-point investigations have been relatively simple
empirical studies of the built-in inter-dependence of
PFS and OS (i.e. OS is a function of PFS), some inves-
tigators have developed statistical models to further
interpret this inter-dependence after removing or
accounting for it [1,3,18]. However, there is a need to
develop new methods that will further improve our
understanding of the relationship between OS and
PFS.
In the current analysis, we ﬁtted parametric models to
failure time data to assess the suitability of PFS as a sur-
rogate of OS in patients with treatment-naı¨ve mRCC,
applying a novel statistical approach to patient-level
data. Our objective was to assess the relationship
between PFS and OS in patients with treatment-naı¨ve
mRCC treated with sunitinib or interferon-alpha
(IFN-a) in a pivotal phase III study [19], in order to
determine the suitability of PFS as a surrogate of OS,
providing supportive evidence to decision makers in
both regulatory and reimbursement authorities, as well
as to treating physicians and their patients.
2. Patients and methods
2.1. Study population
The study population was comprised of patients aged
18 years or older with histologically conﬁrmed mRCC
with a component of clear-cell histology. Key eligibility
criteria included the following: no previous systemic
(including adjuvant or neoadjuvant) therapy for RCC;
measurable disease; Eastern Cooperative Oncology
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hepatic, renal and cardiac function. Additional eligibil-
ity criteria were previously reported [13,19]. All patients
provided written informed consent.
2.2. Study design and dosing regimen
In this phase III, multicenter study, 750 patients with
treatment-naı¨ve mRCC were randomised 1:1 to receive
sunitinib 50 mg/day for 4 weeks on treatment, followed
by 2 weeks oﬀ treatment, in repeated 6-week cycles, or
IFN-a 9 MU as a subcutaneous injection on 3 non-con-
secutive days per week [13,19].
2.3. Post-progression survival (PPS)
To study a relationship between PFS and OS, we
used the diﬀerence between investigator-assessed PFS
and OS (termed PPS; as reported by other research
groups [1]) as an outcome in order to remove inherent
dependencies between PFS and OS. The relationship
between PFS, PPS and OS for a patient (but not for
median data obtained from a group of patients) can
be described by the following equation:
PFSþ PPS ¼ OS
Exclusion of PFS from OS ensured that PPS acted as
a distinct and statistically independent measure of sur-
vival beyond PFS.
To highlight the statistical and methodological
issues that would arise if the direct relationship
between PFS and OS were investigated, a simulation
was performed in which bigger PFS led to smaller
PPS (Fig. 1), with OS values calculated as the sum of
PFS and PPS. PFS had a perfect linear relationship
with OS (i.e. longer PFS was associated with longer
OS). However, it is evident that PFS cannot serve as
a surrogate for OS in this example, because PPS actu-
ally has the opposite relationship with PFS. These
results demonstrate that inherent PFS information as
part of OS can lead to a spurious conclusion for PFS
as a surrogate for OS.Fig. 1. Simulated post-progression survival (PPS) and overall survival
(OS) versus progression-free survival (PFS), in which PPS values were
simulated in a way that longer PFS led to shorter PPS.2.4. Weibull parametric modelling
A Weibull parametric model [20] to failure time data
was ﬁt to determine whether longer PFS was signiﬁ-
cantly and meaningfully predictive of longer PPS, using
all available study data. The model for the response
variable PPS consists of a linear eﬀect for PFS and a
random disturbance term deﬁned as:
Y ¼ aþ b Xþ r e
In this equation, Y is a vector of response values (the log
of PPS), a is an intercept, b is a slope, X represents a vec-
tor of values from the independent predictor (PFS), r is
a scale parameter and e is a vector of errors assumed to
come from a Weibull distribution.
For the above model, the censoring for the PPS inter-
val comprises four diﬀerent possibilities: uncensored
(exact PFS and OS are both known), interval-censored
(PFS and OS are both unknown), left-censored (PFS
unknown, but exact OS known) and right-censored
(exact PFS known, but OS unknown) [21]. For example,
if the PFS censor variable is 0 (meaning that the progres-
sion event occurred), but the OS censor is 1 (meaning
that the patient is alive), PPS is ‘not exactly known’
and this interval is deﬁned as a right-censored interval.
As another example, if both the PFS and OS censor
variables are 0 (meaning that both events occurred),
then the PPS interval is ‘exactly known’ and will not
be censored. We hypothesised that patients with longer
PFS would, on average, have longer survival beyond
PFS (i.e. longer PPS).
2.5. Sensitivity analysis: Kaplan–Meier approach
To apply a Kaplan–Meier (non-parametric) analysis
[22], we deﬁned three approximately equal numbered
groups of patients categorised according to PFS using
all available data (the resulting PFS intervals are based
on the selected percentiles): PFS < 10.2 weeks (<33.3
percentile: n = 243); 10.2 6 PFS < 34.6 weeks (33.3–
66.6 percentile; n = 255); PFSP 34.6 weeks (>66.6 per-
centile; n = 252). Diﬀerences between PPS curves were
assessed using the log-rank test.
All analyses were performed using SAS, version 9.2
(SAS Institute; Cary, NC, USA), with the LIFEREG
procedure to ﬁt the Weibull (parametric) model to fail-
ure time data and the LIFETEST procedure to produce
the Kaplan–Meier (non-parametric) estimates.
3. Results
3.1. Weibull parametric modelling
The Weibull model demonstrated that longer PFS
was signiﬁcantly predictive of longer PPS (P < 0.001;
Fig. 2). The model also allowed prediction of estimated
median PPS from PFS times (Table 1 and Fig. 3). For
Fig. 2. Post-progression survival (PPS) versus progression-free sur-
vival (PFS) by Weibull parametric modelling (all available study data).
Table 1
Predicted post-progression survival (PPS) estimates by progression-
free survival (PFS) from Weibull parametric modelling (all available
study data).
PFS, weeks Predicted median PPS
(95% conﬁdence interval [CI]), weeks
0 38.2 (33.4–43.7)
10 41.0 (36.7–45.7)
20 43.9 (40.1–48.1)
30 47.1 (43.2–51.3)
40 50.4 (45.9–55.4)
50 54 (48.2–60.6)
60 57.9 (50.3–66.7)
70 62.1 (52.3–73.7)
80 66.5 (54.3–81.5)
90 71.3 (56.3–90.3)
100 76.4 (58.4–100.2)
110 81.9 (60.4–111.1)
Fig. 3. Predicted post-progression survival (PPS) by progression-free
survival (PFS) from Weibull parametric modelling (all available study
data).
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PPS time was 43.9 weeks (95% conﬁdence interval [CI]:
40.1–48.1) and, for a patient with PFS of 60 weeks, the
median PPS time was 57.9 weeks (95% CI: 50.3–66.7).Fig. 4. Kaplan–Meier estimates of post-progression survival (PPS)
grouped by progression-free survival (PFS) duration. The three PPS
curves were signiﬁcantly diﬀerent (P < 0.0001).3.2. Sensitivity analysis: Kaplan–Meier approach
A Kaplan–Meier (non-parametric) analysis was car-
ried out to estimate PPS for each of the three PFS
groups (PFS < 10.2 weeks, 10.2 6 PFS < 34.6 weeks
and PFSP 34.6 weeks). Incrementally longer PFS wasassociated with longer PPS, and the three PPS curves
were signiﬁcantly diﬀerent (P < 0.0001; Fig. 4).
4. Discussion
In this study, a discernible and quantiﬁable positive
relationship was found between PFS and PPS time for
individual patients with mRCC randomised to ﬁrst-line
treatment with either sunitinib or IFN-a. Moreover,
when separate parametric modelling was performed
for each treatment arm, the same pattern of results
was observed. These ﬁndings suggest that PFS can be
used as a surrogate end-point for OS in the ﬁrst-line
mRCC setting and provide clinicians with a novel
potential tool for estimating median PPS based on
PFS. Our ﬁndings are consistent with those of two pre-
vious studies evaluating surrogate end-points in mRCC
that demonstrated a relationship between PFS and OS.
In a meta-analysis of 31 RCC trials [10], Delea et al.
(2012) reported a strong correlation between treatment
group eﬀects on PFS and OS times measured by hazard
ratios (r = 0.80). Similarly, a landmark analysis of data
from over 1100 patients who received treatment with
targeted agents found that PFS at 3 and 6 months pre-
dicted OS, with patients who progressed having an
approximately threefold greater risk of death than
patients who did not experience progression at the same
time-point [11]. Finally, a meta-analysis of 4096
advanced RCC patients who received ﬁrst-line targeted
agents in six randomised controlled trials demonstrated
that early PFS was an acceptable intermediate end-point
for OS [23]. The use of PFS as a surrogate for OS is also
supported by meta-analyses of clinical trials in other
tumour types, including colorectal, gastric and ovarian
cancer [4,8,24].
Validation of surrogate end-points is usually based
on the so-called Prentice criterion, which is a set of con-
ditions that relate the treatment eﬀect to the surrogate
end-point and the true end-point [25]. The contribution
of our model primarily lies in the fact that it is based on
individual data and that the inherent dependency
between PFS and OS is removed by studying the
relation between PFS and PPS. When studying the
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used values of PFS and OS directly [7,9,26]. When eval-
uating and quantifying the relationship between PFS
and OS, it is incorrect to use OS as an outcome. In this
report, we assert that when studying the relationship
between PFS and OS, we must evaluate the relationship
between PFS and PPS in order to properly estimate the
true relationship between PFS and OS, one that removes
its built-in inter-dependence. Similarly, a relationship
between time to tumour progression and PPS has been
shown in a previous simulation study in solid tumours
(including mRCC) using new drug application data
[27], thus supporting this approach. Hence, applying
our method produces more reliable results than those
for which surrogacy is based on correlation analysis
between PFS and OS.
While our results are consistent with prior analyses
and potentially more robust, limitations to both the
methodology and extrapolation of these data are recog-
nised, in addition to the usual issues associated with a
retrospective analysis. First, the relationship between
PFS and PPS time reported here can only be used to
provide prognostic information at the patient level
(e.g. estimation of expected survival in a given patient
once progression has occurred). That is, it should be
emphasised that the reported results do not address
the question of whether median PFS can be used as a
surrogate for median OS. To study the relationship
between the median PFS value for a group of patients
and the median OS value for the same group of patients,
the results from a series of studies would need to be
inputted into the described model as a kind of meta-
analysis.
In addition, because our results are based on a trial
conducted during the early era of targeted therapy,
when less treatment options were available, median
PPS estimates for a given PFS may be longer today.
Similarly, the emergence of additional therapies in the
future with diﬀerent mechanisms of action, e.g.
immune-mediated treatments, may confer beneﬁt to
patients in a diﬀerent way and modify the relationship
between PFS and PPS observed here. In summary, fur-
ther research is needed to determine whether the data,
speciﬁc to this trial, are applicable beyond the current
study and whether they are relevant for second and sub-
sequent lines of therapy, although the model itself
should be broadly applicable.
Other potential surrogate end-points may allow
faster or simpler methods to evaluate and distinguish
response between therapies. For example, in an analy-
sis of mRCC patients from the TARGET (sorafenib
versus placebo, n = 84) and RECORD (everolimus
versus placebo, n = 43) phase III trials [28], treat-
ment-associated tumour growth rate (TGR) was
shown to be independently associated with PFS and
OS. As per the authors, TGR provided subtle and
quantitative characterisation of drug activity at theﬁrst evaluation and revealed clear drug-speciﬁc proﬁles
at progression.
Novel statistical approaches of the type employed in
this study enrich the interpretation and understanding
of the relationship between OS and surrogate end-
points. In the future, ﬁnding a surrogate end-point in
oncology is likely to become increasingly important as,
with the introduction of more new therapies, it will
become progressively more challenging to demonstrate
an OS beneﬁt. This becomes increasingly true in the
presence of numerous treatment and sequencing
options. Indeed, with the exception of one temsirolimus
trial [29], no drug has unequivocally demonstrated an
OS beneﬁt in RCC. Yet, a trend for increasing OS over
time has been observed, speciﬁcally in clinical trials of
mRCC as data read out [30]. The complexity of proving
an OS beneﬁt in the current treatment landscape may
lead to problems with the regulatory approval process
and could delay patients’ access to new treatments.
Thus, the establishment of a valid and sound relation-
ship between PFS and OS, in addition to implications
for clinical trial design and management, could help to
support regulators and payers in their decision-making,
and ultimately allow patients to gain faster access to life-
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